SCHEMBL1450641

SCHEMBL1450641

Cc1[nH]c(-c2ccccc2)cc1C(=O)C(=O)N1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
HTR2A P28223 2/20 0.49
HTR2C P28335 2/20 0.49
SLC6A4 P31645 2/20 0.49
MAPT P10636 5/20 0.48
HTT P42858 4/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.47
RECQL P46063 1/20 0.47
TACR3 P29371 1/20 0.46
CCR1 P32246 1/20 0.45
BRD4 O60885 1/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 1/20 0.45
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1450710 0.91 KMT2A (0.57) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450141 0.89 KMT2A (0.64) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450101 0.88 KMT2A (0.67) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1451370 0.88 KMT2A (0.50) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450839 0.88 KMT2A (0.55) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1451384 0.88 KMT2A (0.53) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450406 0.85 KMT2A (0.55) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450195 0.85 KMT2A (0.54) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450650 0.85 BRD4 (0.49) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450740 0.84 KMT2A (0.50) KMT2AMEN1HTR2AHTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167487-B1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2015-02-18 EP claimed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US claimed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US claimed
EP-2167487-B1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2015-02-18 EP disclosed
EP-2167487-B1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2015-02-18 EP disclosed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US disclosed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US disclosed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US disclosed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US disclosed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US disclosed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US disclosed
WO-2008155022-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS P2RY12, P2RY11, P2RY13 KMT2A 4670/4885MEN1 3103/4885HTR2A 1052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.